Anti-Sirpa Antibodies and Methods of Use Thereof
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 3 of these applications claim priority to application 62/676,813, filed May 25, 2018. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 11,976,119 | Anti-SIRPa Antibodies and Methods of Use Thereof In force · High confidence | Alector LLC | In force | High confidence | ||
| US 12,258,410 | Anti-SIRPa Antibodies and Methods of Use Thereof In force · High confidence | Alector LLC | In force | High confidence | ||
| US 11,319,373 | Anti-Sirpa Antibodies and Methods of Use Thereof In force · High confidence | Alector LLC | In force | High confidence | ||
| Application 19/057,127 | Anti-SIRPa Antibodies and Methods of Use Thereof Pending Not granted | Alector LLC | Pending | Not granted | not computed |
4 of 4 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
3 of these are in force and held by Alector LLC.
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.